 |
February 14, 2008
Y's Therapeutics announces FDA acceptance of IND to conduct Phase I clinical trial for
YSCMA in the USA
|
 |
|
January 15, 2008
We have update the employment information at the our website.
|
|
|
November 1, 2007
Y's Therapeutics Appoints Takaharu Itoh as CFO on November 1, 2007
|
|
|
August 1, 2007
Y's Therapeutics Announced the change of the board members on August 1, 2007
|
|
|
May 2, 2007
Y's Therapeutics Initiates Phase II Trial with YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury
|
|
|
April 24, 2007
Y's Therapeutics Completes Enrollment of Phase II Trial in the U.S. With YSPSL for Prevention of Delayed Graft Function in Renal Transplantation |
|
|
Oct 3, 2006
Y's Therapeutics Raises 2.3 billion yen (US $20 million) in Series D Financing |
|
|
Jul 21, 2006
Y's Therapeutics Clinical-Stage Compound YSPSL Granted Orphan Status in U.S. and Europe |
|
|
Feb 24, 2006
Y's Therapeutics appoints Nobuo Kato as President and CEO, and Motoharu Higashizono as Board of Director and COO on Dec 22, 2005 |
|
|
⇒ more |
|
